108 related articles for article (PubMed ID: 5306738)
1. [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].
Mathé G; Schwarzenberg L; Hayat M; Schneider M
Rev Fr Etud Clin Biol; 1968 Dec; 13(10):951-60. PubMed ID: 5306738
[No Abstract] [Full Text] [Related]
2. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
Chello PL; Sirotnak FM
Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
[TBL] [Abstract][Full Text] [Related]
3. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
Burns ER; Scheving LE
Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
[No Abstract] [Full Text] [Related]
4. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
Pouillart P; Huong TH; Lhéritier J
Bull Cancer; 1974; 61(4):509-26. PubMed ID: 4458834
[No Abstract] [Full Text] [Related]
5. An assessment of massive-dose chemotherapy of malignant disease.
Bergsagel DE
Can Med Assoc J; 1971 Jan; 104(1):31-6. PubMed ID: 4322068
[No Abstract] [Full Text] [Related]
6. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
Skipper HE; Schabel FM; Mellett LB; Montgomery JA; Wilkoff LJ; Lloyd HH; Brockman RW
Cancer Chemother Rep; 1970 Dec; 54(6):431-50. PubMed ID: 5527023
[No Abstract] [Full Text] [Related]
7. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
Scheving LE; Burns ER; Halberg F; Pauly JE
Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
[TBL] [Abstract][Full Text] [Related]
8. The effect of the sequence of administration of cytoxan and methotrexate on the life-span of L1210 leukemic mice.
Straus MJ; Mantel N; Goldin A
Cancer Res; 1972 Feb; 32(2):200-7. PubMed ID: 5058180
[No Abstract] [Full Text] [Related]
9. Formal discussion: the clinical pharmacology of anti-leukemia agents.
Holland JF
Cancer Res; 1965 Oct; 25(9):1639-41. PubMed ID: 5295365
[No Abstract] [Full Text] [Related]
10. [Effects of the method of reinduction during the treatment of acute lymphoblastic leukemia].
Jacquillat C; Weil M; Boiron M
Therapeutique; 1971 Apr; 47(4):403-5. PubMed ID: 5284341
[No Abstract] [Full Text] [Related]
11. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia].
Paśnicki M
Wiad Lek; 1995; 48(1-12):194-7. PubMed ID: 9638239
[No Abstract] [Full Text] [Related]
12. Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia.
Chello PL; Sirotnak FM; Dorick DM; Moccio DM
Cancer Treat Rep; 1979; 63(11-12):1889-94. PubMed ID: 526921
[TBL] [Abstract][Full Text] [Related]
13. Variant translocations of 11q23 in infant acute lymphoblastic leukemia (ALL): do outcomes differ from t(4;11)?
Jakab Z; Balogh E; Karászi E; Kappelmayer J; Kiss C; Oláh E
Med Pediatr Oncol; 2002 Jul; 39(1):63-5. PubMed ID: 12116086
[No Abstract] [Full Text] [Related]
14. Chemotherapy and the life cycle of leukaemic cells. A comparison between the growth characteristics of human acute leukaemia and the murine leukaemia L 1210.
Benckhuijsen C
Folia Med Neerl; 1969 Dec; 12(2):74-84. PubMed ID: 4894168
[No Abstract] [Full Text] [Related]
15. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
16. [On the rotating (cyclic) therapy of acute leukemias according to the MEPO scheme].
Oehme J
Dtsch Med Wochenschr; 1967 Oct; 92(41):1866-9. PubMed ID: 6057145
[No Abstract] [Full Text] [Related]
17. Rationale of chemotherapeutic adjuvant treatment.
Goldin A
Arch Geschwulstforsch; 1978; 48(7):627-35. PubMed ID: 736743
[No Abstract] [Full Text] [Related]
18. Evaluation of combination chemotherapy with three drugs.
Goldin A; Venditti JM; Mantel N; Kline I; Gang M
Cancer Res; 1968 May; 28(5):950-60. PubMed ID: 5652309
[No Abstract] [Full Text] [Related]
19. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
20. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
Kim K; Blechman WJ; Riddle VG; Pardee AB
Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
